Sat.Dec 14, 2019 - Fri.Dec 20, 2019

article thumbnail

Decentralized Clinical Trials Enable Participation for Immobile Patients

VirTrial

Clinical trials require a significant commitment from patients, particularly in regard to travel time to research sites for regular visits. Consider the additional patient burden involved in clinical trials for patients with paralysis, dementia, or other conditions that make travel difficult or impossible. Their immobility typically prevents them from participating in traditional on-site trials.

article thumbnail

The effect of patent expiration on sales of branded competitor drugs in a therapeutic class

Drug Patent Watch

DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and…. The post The effect of patent expiration on sales of branded competitor drugs in a therapeutic class appeared first on DrugPatentWatch - Make Better Decisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Best Place to Live to Get Clinical Research Jobs

ECRG Media's Clinical Research Podcast

Best Place To Live To Get Clinical Research Opportunities This episode we talk about which clinical research cities have the most opportunities. Where should you move if your going to move to a city in order to get a clinical research job. Don't forget to Subscribe for new content! Subscribe: [link] Call or Text: 910-502-3732 Email: eliteclinicalgroup@gmail.com Podcast: [link] Steemit: [link] Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: [link] » All Videos: [link] » Interview

article thumbnail

Commercial Advisory Group

Syneos Health

Success in today’s commercial market environment demands that biopharmaceutical firms build profitable portfolios while establishing and demonstrating asset value earlier in the development life cyc

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

EIT Health launches 2020 Wild Card with €4 million investment for innovations addressing Women’s Health and Digital Therapeutics.

Drug Discovery Today

EIT Health will invest up to €2 million in two start-ups that offer the most effective and disruptive solutions to address either Women’s Health or Digital Therapeutics.Applications for the Wild Card programme are open until 9th February 2020.

40
article thumbnail

Trump Administration Announces FDA-Proposed Rule and Guidance to Allow Prescription Drug Importation

Pharmacy Checkers

The FDA has done something that prescription drug importation advocates had possibly given up on. Not me. The agency drafted a new proposed rule to allow importation from Canada of lower-cost drugs and industry guidance for drug manufacturers to import their FDA-approved foreign drug versions, for which they can charge lower prices. The proposed rule provides specifics so that states contemplating or already formulating wholesale drug importation programs have a shot at gaining approval for thos

Drugs 73

More Trending

article thumbnail

MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35

Drug Discovery Today

Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.

40
article thumbnail

Catalent Partners with Bridge Therapeutics on Formulation, Development and Production of New Opioid Addiction Treatment

Drug Discovery Today

Somerset, N.J. & Birmingham, Ala.– December 10, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis® orally disintegrating tab

article thumbnail

The Current issue of “The view from here” is concerned with The Best of 2019

Drug Discovery Today

The topic of this month’s newsletter from Drug Discovery Today is “The Best of 2019”.

Drugs 40
article thumbnail

Start Codon and One Nucleus partner to support UK life science ecosystem

Drug Discovery Today

Start Codon cohort companies to receive One Nucleus membership benefits

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

ELRIG UK and British Pharmacological Society collaborate to improve scientific exchange in UK drug discovery

Drug Discovery Today

Major learned societies initiate two-year strategic alliance

Drugs 40